Kamada Ltd. (NASDAQ:KMDA) reported net income for the first quarter of $ 1.26 million or $ 0.03 per share, compared to loss $ 3.98 million or $ 0.11 per share for the year-ago quarter.
The Ness Ziona, Israel based company recorded revenue for first quarter rose 50% to $ 17.44 million from $ 11.65 million in the same quarter last year.
Analysts polled by Thomson Reuters expected KMDA to report income of $ 0.02 per share on revenue of $ 24.02 million for the first quarter.
Kamada is excited about the recent U.S. launch of KEDRAB®, our anti-rabies IgG product, by Kedrion, our commercial partner in the U.S. our second FDA approved product to be commercialized in the U.S., is already positively impacting our business, as a meaningful portion of our first quarter 2018 revenues is derived from sales of this product, said Amir London, CEO of Kamada
At the same time, Kamada Ltd. anticipates full year 2018 revenue to be $116 million to $120 million.